ライフサイエンスコーパス: extended-spectrum

1 phylococcus aureus, 27% Pseudomonas, and 10% extended-spectrum beta-lactamase-producing bacteria, wit

2 0 allele, and the production of the CTX-M-15 extended spectrum beta-lactamase (ESBL).

3 We used PCR to detect CTX-M in all 291 extended-spectrum cephalosporin-resistant gram-negative

4 1 (AmpC), 2b (TEM-1, TEM-2, and SHV-1), 2be (extended spectrum beta-lactamases [ESBLs] and K1), and 2

5 Forty-three wild-type (WT) strains, 42 extended-spectrum beta-lactamase (ESBL) producers, 18 ES

6 icillin-resistant Staphylococcus aureus [5], extended-spectrum beta-lactamase-producing Klebsiella pn

7 The assay was performed on 56 extended-spectrum-beta-lactamase (ESBL) E. coli isolates

8 ach of the three described isoenzymes and 69 extended-spectrum beta-lactamase-producing clinical isol

9 Specifically, the class A extended-spectrum beta-lactamases (ESBLs) and inhibitor-

10 The emergence of CTX-M class A extended-spectrum beta-lactamases poses a serious health

11 th N1MS exhibiting superior activity against extended spectrum beta lactamase producers, despite dimi

12 High activity against extended-spectrum beta-lactamase, methicillin-resistant

13 ctivity of ceftazidime and cefpirome against extended-spectrum cephalosporin and Sme-1 containing car

14 platforms identified susceptibility against extended-spectrum cephalosporins and carbapenems in >90%

15 Although extended-spectrum beta-lactamases (ESBLs) hydrolyze ceph

16 of the strains were resistant to ampicillin, extended-spectrum cephalosporins, and aminoglycosides, i

17 ements for the hydrolysis of ceftazidime, an extended spectrum cephalosporin commonly used to treat s

18 and independent of AIRE, which may cover an extended spectrum of peripheral Ags in the thymus.

19 enerate peptide sequence tags (PSTs) from an extended spectrum graph.

20 The beta-lactamase of E. cloacae GC1, an extended spectrum mutant of the P99 enzyme, rapidly hydr

21 lelic mutations in KDSR are implicated in an extended spectrum of disorders of keratinization in whic

22 ch that uncovered the key role of IL-1 in an extended spectrum of immune dysregulatory conditions.

23 We show that BlaC is an extended spectrum beta-lactamase (ESBL) with high levels

24 nt serine carbapenemase), whereas PenI is an extended spectrum beta-lactamase.

25 of two enzymes, with only one possessing an extended spectrum of activity.

26 meolysin", ClyR, with robust activity and an extended-spectrum streptococcal host range against most

27 at are widely used in the clinic, such as an extended-spectrum beta-lactam antibiotic amoxicillin/cla

28 d urinary tract infection (UTI) caused by an extended-spectrum beta-lactamase (ESBL)-producing, multi

29 ized patients were more likely to develop an extended-spectrum beta-lactamase-producing Enterobacteri

30 atory have shown that the enzyme exhibits an extended-spectrum phenotype, with very high levels of pe

31 Isavuconazole is an extended-spectrum triazole with in vitro activity agains

32 y in the Omega-loop may form the basis of an extended-spectrum activity of class C beta-lactamases ag

33 Probable transmission of an extended-spectrum-beta-lactamase-producing Escherichia c

34 re used to identify resistance integrons and extended spectrum beta-lactamase genes.

35 rovar Newport MDR-AmpC expressing TEM-1b and extended-spectrum beta-lactamase SHV-12 was isolated fro

36 s aureus (MRSA), Pseudomonas aeruginosa, and extended-spectrum beta-lactamases as ROs.

37 , the test accurately distinguished AmpC and extended-spectrum beta-lactamase production and differen

38 , carbapenem-resistant Escherichia coli, and extended-spectrum beta-lactamase-producing Klebsiella pn

39 nem-nonsusceptible (excluding ertapenem) and extended-spectrum cephalosporin-resistant Escherichia co

40 pled with restriction of fluoroquinolone and extended-spectrum beta-lactam use to control both the ma

41 with susceptibility to fluoroquinolones and extended-spectrum cephalosporins.

42 the implications of fluoroquinolone (FQ) and extended-spectrum cephalosporin plus cephamycin (AmpC) r

43 res, including complexes with inhibitors and extended-spectrum antibiotics, were determined by X-ray

44 and derepressed chromosomal beta-lactam and extended-spectrum beta-lactamase-producing Enterobacter

45 BL carbapenemases, AmpC beta-lactamases, and extended-spectrum beta-lactamases were tested.

46 especially extended-spectrum macrolides and extended-spectrum fluoroquinolones (P<.001 for all trend

47 of isolates were resistant to penicillin and extended-spectrum cephalosporins.

48 zed by resistant intestinal bacteria such as extended-spectrum beta-lactamase-producing Enterobacteri

49 Newer beta-lactamases such as extended-spectrum beta-lactamases (ESBLs), transferable

50 ROs such as methicillin-resistant S. aureus, extended-spectrum beta-lactamase-producing, and carbapen

51 d by mixed resistant Gram-negative bacteria, extended-spectrum beta-lactamase-producing Enterobacteri

52 he benefits and safety of azithromycin-based extended-spectrum prophylaxis in women undergoing nonele

53 targeted pathogens (Acinetobacter baumannii, extended-spectrum beta-lactamase-producing Gram-negative

54 Clinical resistance to both extended-spectrum cephalosporins and beta-lactam-beta-la

55 e primary treatment for infections caused by extended-spectrum beta-lactamase (ESBL)-producing Klebsi

56 The continued rise in infections caused by extended-spectrum beta-lactamase (ESBL)-producing pathog

57 ad ventilator-associated pneumonia caused by extended-spectrum beta-lactamase-producing Enterobacteri

58 the isolated bacteria, infections caused by extended-spectrum beta-lactamase-producing Enterobacteri

59 ment considerations for infections caused by extended-spectrum beta-lactamase-producing organisms, Am

60 ary broad-spectrum beta-lactams, mediated by extended-spectrum beta-lactamase (ESBL) enzymes, is an i

61 pound also inhibits irreversibly the class C extended-spectrum GC1 beta-lactamase (IC(50) = 6.2 nM).

62 stance against beta-lactams, cephalosporins (extended-spectrum beta-lactamase-producing type SHV-12),

63 ia coli strains producing well-characterized extended-spectrum, AmpC, or carbapenem-hydrolyzing beta-

64 bs on two selective culture media, CHROMagar extended-spectrum-beta-lactamase (ESBL) and vancomycin,

65 The structure of a chromosomal extended-spectrum beta-lactamase (ESBL) having the abili

66 ncing of previously uncharacterized clinical extended-spectrum beta-lactamase (ESBL)-producing Escher

67 Combined extended-spectrum beta-lactamase production (blaTEM-1 ge

68 ic residues, including those known to confer extended-spectrum activity.

69 c serine; the question of how they conferred extended-spectrum activity arose.

70 anic acid (CLAV) were also tested to confirm extended-spectrum beta-lactamase (ESBL) carriage.

71 rbapenem-resistant Enterobacteriaceae (CRE), extended-spectrum beta-lactamase (ESBL)-producing Entero

72 performed to assess their ability to detect extended-spectrum beta-lactamases (ESBLs) in members of

73 Eight (21.0%) of 38 labs failed to detect extended-spectrum cephalosporin or aztreonam resistance

74 rd CLSI disk diffusion methods for detecting extended-spectrum beta-lactamases (ESBLs) and with cefep

75 ening and confirmation methods for detecting extended-spectrum beta-lactamases (ESBLs) apply only to

76 sistant enterococcus, Clostridium difficile, extended-spectrum beta-lactamase-producing gram-negative

77 Approximately 1.0% of strains displayed extended-spectrum beta-lactamase (ESBL) activity.

78 Representative isolates from 10 distinct extended-spectrum beta-lactamase-producing strains of Kl

79 esistant Staphylococcus aureus) and ESBL-EC (extended-spectrum beta-lactamase-producing Escherichia c

80 increasingly associated with plasmid-encoded extended-spectrum beta-lactamases (ESBLs) and carbapenem

81 biotics arises from a chromosomally encoded, extended spectrum, class A beta-lactamase, BlaC.

82 rizontal dissemination of the genes encoding extended spectrum beta-lactamases (ESBLs) via conjugativ

83 se of nonrecommended antibiotics, especially extended-spectrum macrolides and extended-spectrum fluor

84 hvKP strains, 17% (5/29) of which expressed extended-spectrum beta-lactamase.

85 In a low prevalence area for extended spectrum betalactamases (ESBL) and multiresista

86 that have increased hydrolytic activity for extended-spectrum antibiotics such as ceftazidime.

87 ined using the revised CLSI breakpoints, for extended-spectrum-beta-lactamase (ESBL)-producing Escher

88 Active surveillance culture for extended-spectrum beta-lactamase-producing Enterobacteri

89 talization were independent risk factors for extended-spectrum beta-lactamase-producing Enterobacteri

90 As routine testing of clinical isolates for extended-spectrum beta-lactamase (ESBL) production (scre

91 ught to assess the interest of screening for extended-spectrum beta-lactamase-producing Enterobacteri

92 Screening for extended-spectrum beta-lactamase-producing Enterobacteri

93 ts and used the double disk synergy test for extended-spectrum beta-lactamase-producing Enterobacteri

94 Clinical laboratories test for extended-spectrum beta-lactamases (ESBLs) for epidemiolo

95 To determine whether confirmatory tests for extended-spectrum beta-lactamase (ESBL) production in Es

96 ic structure of the Enterobacter cloacae GC1 extended-spectrum class C beta-lactamase, inhibited by a

97 ta-lactamases are one of the fastest growing extended-spectrum beta-lactamase (ESBL) families found i

98 e fatal cases, and two of these isolates had extended-spectrum beta-lactamase activity.

99 resistant gram-negative bacteria that harbor extended-spectrum beta-lactamases (ESBLs) are increasing

100 Escherichia coli, such as strains harboring extended-spectrum beta-lactamase (ESBL) genes, frequentl

101 riant TEM and SHV enzymes that can hydrolyze extended-spectrum antibiotics.

102 utations that permit the enzyme to hydrolyze extended-spectrum cephalosporins or to avoid inactivatio

103 Significant reductions were seen in extended-spectrum penicillins (p=0.0080), carbapenems (p

104 resistance to many cephalosporins including extended spectrum cephalosporins.

105 tiple antibiotic resistance genes, including extended spectrum beta-lactamases, for which therapeutic

106 t to at least nine antimicrobials (including extended-spectrum cephalosporins), known as serotype New

107 biotic resistance evolution, we investigated extended-spectrum mutants of class C beta-lactamases, wh

108 CTX-M extended-spectrum beta-lactamases (ESBLs) have emerged a

109 Currently, rising problems include CTX-M extended-spectrum beta-lactamases (ESBLs), plasmid-media

110 methoxy-ticarcillin) shows stability to most extended spectrum beta-lactamases, but is considered ina

111 ug-resistant Pseudomonas aeruginosa and most extended-spectrum beta-lactamase (ESBL)-producing Entero

112 Isavuconazole is a new extended-spectrum triazole with activity against yeasts,

113 d efficacy and safety of posaconazole, a new extended-spectrum triazole, as salvage therapy for IFIs

114 ivate penicillins and cephalosporins but not extended-spectrum antibiotics.

115 arisen multiple times in naturally occurring extended-spectrum TEM alleles, seven were recovered mult

116 cid substitutions in the naturally occurring extended-spectrum TEM alleles.

117 CTX-M enzymes are an emerging group of extended spectrum beta-lactamases (ESBLs) that hydrolyze

118 ly of beta-lactamases constitutes a group of extended spectrum resistance enzymes that hydrolyze peni

119 However, the rise of extended spectrum beta-lactamase (ESBL) producing bacter

120 cent study in Texas showed that up to 70% of extended-spectrum beta-lactamase (ESBL)-containing membe

121 mp inhibitors (PPIs) were rectal carriers of extended-spectrum beta-lactamase-producing Enterobacteri

122 One unreported case of extended-spectrum-beta-lactamase (ESBL)-producing Salmon

123 ly significant for postintervention cases of extended-spectrum beta-lactamase-producing organisms (P

124 t technologies permit the rapid detection of extended-spectrum beta-lactamase (bla(ESBL)) and Klebsie

125 impact of preenrichment on the detection of extended-spectrum beta-lactamase-producing Enterobacteri

126 function is valuable for the development of extended-spectrum NNRTIs.

127 The worldwide dissemination of extended-spectrum-beta-lactamase (ESBL)- and carbapenema

128 The emergence of extended-spectrum beta-lactamase (ESBL) and plasmid-medi

129 amase inhibitors has driven the evolution of extended-spectrum beta-lactamases (ESBLs) that possess t

130 iated with significantly higher frequency of extended-spectrum beta-lactamase-producing Enterobacteri

131 the Ser238 side chain to the oxime group of extended-spectrum antibiotics.

132 e of the G238S substitution in hydrolysis of extended-spectrum antibiotics.

133 substitution display increased hydrolysis of extended-spectrum antibiotics.

134 enzyme to provide an increased hydrolysis of extended-spectrum cephalosporins or an increased resista

135 Timely identification of extended-spectrum beta-lactamase (ESBL) bacteremia can i

136 Thus, changing the interpretation of extended-spectrum cephalosporins and aztreonam results f

137 y was to determine if the interpretations of extended-spectrum and advanced-spectrum cephalosporins (

138 The introduction of extended-spectrum cephalosporins and beta-lactamase inhi

139 LSI); and for isolates for which the MICs of extended-spectrum cephalosporins were > or =1 microg/ml

140 the pAmpC enzymes may yield similar MICs of extended-spectrum cephalosporins, many of which fall wit

141 Furthermore, a number of extended-spectrum beta-lactamases (ESBL) were identified

142 in 23 states to determine the occurrence of extended-spectrum beta-lactamase (ESBL) and AmpC beta-la

143 timicrobial resistance and the occurrence of extended-spectrum beta-lactamases (ESBLs) modulated by f

144 obacteriaceae colonization as a predictor of extended-spectrum beta-lactamase-producing Enterobacteri

145 lates were also screened for the presence of extended-spectrum beta-lactamase (ESBL) activity.

146 p. and Escherichia coli with the presence of extended-spectrum beta-lactamase (ESBL) and plasmid-medi

147 ceptibility testing revealed the presence of extended-spectrum beta-lactamase (ESBL) resistance.

148 The prevalence of extended-spectrum beta-lactamase (ESBL)-mediated resista

149 The worldwide prevalence of extended-spectrum beta-lactamase (ESBL)-producing Entero

150 t neonatal sepsis, with a high prevalence of extended-spectrum beta-lactamase-producing organisms.

151 ates included porin mutants and producers of extended-spectrum beta-lactamases (ESBLs), AmpCs, K1, an

152 rce of this resistance is from production of extended-spectrum (ES) beta-lactamases by bacteria.

153 20-week period were tested for production of extended-spectrum beta-lactamases (ESBLs) by the double-

154 The ICU acquisition rate of extended-spectrum beta-lactamase-producing Enterobacteri

155 Studies about transmission rates of extended-spectrum beta-lactamase (ESBL)-producing Entero

156 The determinants of the spread of extended-spectrum beta-lactamase-producing Escherichia c

157 The emergence and spread of extended-spectrum beta-lactamases and carbapenemases amo

158 Strains of extended-spectrum beta-lactamase-producing Klebsiella pn

159 cillin-tazobactam (PTZ) for the treatment of extended-spectrum beta-lactamase (ESBL) bacteremia is co

160 e exists with the detection and treatment of extended-spectrum beta-lactamase-producing organisms (Kl

161 producing CTX-M-15, the predominant type of extended-spectrum beta-lactamase (ESBL) associated with

162 ance have appeared in response to the use of extended-spectrum beta-lactam antibiotics (e.g., ceftazi

163 plant Patients) has provided pivotal data on extended-spectrum beta-lactamase (ESBL)-producing Entero

164 was defined by the isolation of at least one extended-spectrum beta-lactamase-producing Enterobacteri

165 roth microdilution (BMD) MIC of at least one extended-spectrum cephalosporin was >/=2 micro g/ml.

166 tance, defined as resistance to at least one extended-spectrum cephalosporin, one aminoglycoside, and

167 ally fluoroquinolone-resistant (FQ-R) and/or extended-spectrum beta-lactamase (ESBL)-producing, has e

168 o >128 micro g/ml and the MICs for the other extended-spectrum cephalosporins were highly variable.

169 The VITEK 2 and Phoenix extended-spectrum beta-lactamase (ESBL) detection system

170 lasmid-mediated quinolone resistance (PMQR), extended-spectrum beta-lactamases (ESBL) and AmpC beta-l

171 ia coli and Klebsiella pneumoniae possessing extended-spectrum class A beta-lactamases (ESBLs) contin

172 screened by the MicroScan system as possible extended-spectrum-beta-lactamase (ESBL)-producing organi

173 Sensitivity and specificity of prior extended-spectrum beta-lactamase-producing Enterobacteri

174 Strains of Klebsiella frequently produce extended-spectrum beta-lactamases, and infections with t

175 a, especially Klebsiella pneumoniae, produce extended-spectrum beta-lactamases (ESBLs) as an antibiot

176 Gram-negative bacteria that produce extended-spectrum- and metallo-beta-lactamases are being

177 d 109 (80%) isolates, respectively, produced extended-spectrum beta-lactamases (ESBL).

178 trols consisted of 50 isolates that produced extended-spectrum beta-lactamases (ESBLs), AmpCs (includ

179 hia coli, Escherichia coli (ESBL) (producing extended spectrum beta-lactamases) and Morganella morgan

180 stance mechanisms, including those producing extended-spectrum beta-lactamase enzymes.

181 Other residues promoting extended-spectrum activity in K1 include the side-chains

182 l receiving standard antibiotic prophylaxis, extended-spectrum prophylaxis with adjunctive azithromyc

183 Rather, extended spectrum activities can emerge from the backgro

184 Reduced extended-spectrum cephalosporin susceptibility is predom

185 The majority of studies reported extended-spectrum beta-lactamase (ESBL)-producing Entero

186 Studies reporting extended-spectrum beta-lactamase-producing Enterobacteri

187 robacteriaceae (CRE), blaNDM-1, and selected extended-spectrum beta-lactam (ESBL) resistant bacteria

188 istically demonstrates resistance to several extended-spectrum antimicrobial agents.

189 nella enterica serovar Typhi isolate showing extended spectrum beta-lactamase (ESBL) production in th

190 herichia coli DH10B strains bearing bla(SHV) extended-spectrum and inhibitor-resistant beta-lactamase

191 of prior colonization to predict subsequent extended-spectrum beta-lactamase-producing Enterobacteri

192 teus mirabilis with an ertapenem-susceptible extended-spectrum-beta-lactamase (ESBL)-positive phenoty

193 r case, and literature review, suggests that extended-spectrum penicillins, tetracycline, and trimeth

194 The extended spectrum of mtDNA rearrangements in single cell

195 These structural differences may explain the extended spectrum activity of GC1 against this class of

196 When used for the extended spectrum of endothelial pathologies, DMEK prove

197 nother mutant of the P99 beta-lactamase, the extended spectrum GC1 enzyme, also has space available f

198 The extended-spectrum cephalosporin resistance in these noso

199 The extended-spectrum cephalosporins--cefixime and ceftriaxo

200 The extended-spectrum triazoles were most active in the Asia

201 phalosporins, we found genes that encode the extended-spectrum beta-lactamases CTX-M-2, CTX-M-14, and

202 rolytic activity of the G238S enzyme for the extended-spectrum antibiotics cefotaxime and ceftazidime

203 wild-type level activity or greater for the extended-spectrum cephalosporin ceftazidime and the mono

204 nicillins and cephalosporins, except for the extended-spectrum cephalosporins.

205 Although new enzymes in the extended-spectrum beta-lactamase (ESBL) families are fre

206 Two are found in the extended-spectrum beta-lactamases most frequently identi

207 Additionally, ARGs, including the extended-spectrum ss-lactam- and aminoglycoside-resistan

208 ylation (k(2)) and deacylation (k(3)) of the extended-spectrum beta-lactamase were enhanced.

209 tween the restriction digest patterns of the extended-spectrum beta-lactamase-encoding plasmids were

210 All of the extended-spectrum beta-lactamases were encoded by self-t

211 spergillus spp. was observed for each of the extended-spectrum triazoles and varied by species over t

212 te on the enzyme rather than directly to the extended-spectrum antibiotic.

213 producers and reported the results with the extended-spectrum cephalosporins and aztreonam as resist

214 xime, ceftazadime, and aztreonam, i.e., the "extended-spectrum" phenotype.

215 rams antibiotic disks, the fraction of these extended-spectrum beta-lactamase (ESBL)-producing isolat

216 Autoantibodies of this extended spectrum may enhance autoimmune serological tes

217 apbpF DeltaponA mutant and triple mutants to extended spectrum cephalosporins (ceftriaxone and cefepi

218 gonorrhoeae with decreased susceptibility to extended spectrum cephalosporins raises the prospect of

219 The failure was attributed to extended-spectrum beta-lactamase (ESBL) acquisition by t

220 enes fell within the susceptible category to extended-spectrum cephalosporins, raising concern over c

221 ce of community-associated infections due to extended-spectrum beta-lactamase (ESBL)-producing Escher

222 ment of bloodstream infections (BSIs) due to extended-spectrum beta-lactamase-producing Enterobacteri

223 halosporin and monobactam antibiotics due to extended-spectrum beta-lactamases (ESBLs) has resulted i

224 nd categorize evidence for human exposure to extended-spectrum beta-lactamase-producing Enterobacteri

225 alence and dynamics of resistance markers to extended-spectrum cephalosporins, macrolides, and fluoro

226 eumoniae that exhibited nonsusceptibility to extended-spectrum cephalosporins were detected.

227 rolytic spectrum for bacterial resistance to extended-spectrum antibiotics.

228 Resistance to extended-spectrum beta-lactam antibiotics has led to a g

229 robacter spp. and also mediate resistance to extended-spectrum cephalosporins and aztreonam in additi

230 -negative bacilli that mediate resistance to extended-spectrum cephalosporins and aztreonam.

231 -negative bacilli that mediate resistance to extended-spectrum cephalosporins and aztreonam.

232 (ESBL-type enzymes that confer resistance to extended-spectrum cephalosporins and carbapenems) presen

233 e in Enterococcus faecium, and resistance to extended-spectrum cephalosporins in Klebsiella pneumonia

234 Resistance to extended-spectrum cephalosporins is associated with clin

235 Enterobacteriaceae can confer resistance to extended-spectrum cephalosporins, aztreonam, and penicil

236 and a control strain that was susceptible to extended-spectrum cephalosporins to 38 laboratories in C

237 ance to carbapenems, which are used to treat extended-spectrum beta-lactamase (ESBL)-producing bacter

238 well as the D49A and F142A mutants, with two extended spectrum beta-lactamases (the G238S and the E10

239 plasmid-borne AmpC gene (bla CMY-42) and two extended-spectrum beta-lactamase genes (bla CTX-M-15 and

240 oacae bloodstream isolates produced SHV-type extended-spectrum beta-lactamases (ESBLs) in addition to

241 In 45 isolates, 49 previously unrecognized extended-spectrum beta-lactamase or plasmid AmpC targets

242 isolates and three Klebsiella isolates) were extended-spectrum beta-lactamase producers.

243 ns of non-Salmonella Enterobacteriaceae with extended spectrum beta-lactamase (ESBL) or fluoroquinolo

244 vided data on ICU-acquired colonization with extended-spectrum beta-lactamase-producing Enterobacteri

245 etermine the risk of stool colonization with extended-spectrum cephalosporin-resistant gram-negative

246 ted pneumonia, 40 (6.8%) were colonized with extended-spectrum beta-lactamase-producing Enterobacteri

247 previously detected as being colonized with extended-spectrum beta-lactamase-producing Enterobacteri

248 of KPC-producing E. coli when compared with extended-spectrum beta-lactamase-producing E. coli.

249 italized patients colonized or infected with extended-spectrum beta-lactamase-producing Escherichia c

250 ization is a risk factor for infections with extended-spectrum beta-lactamase (ESBL)-producing organi

251 coli and Klebsiella pneumoniae isolates with extended-spectrum beta-lactamases (ESBLs) or AmpC cephal

252 ion at C12 led to 12-epi-pleuromutilins with extended-spectrum antibacterial activity, including acti

253 the colonization of the digestive tract with extended-spectrum beta-lactamase-producing Enterobacteri